Bronchodilator response: PRAM reassessment and escalation criteria

Quick take: A bronchodilator response test measures how well your lungs open after a medication, and the PRAM (Pediatric Respiratory Assessment Measure) reassessment helps clinicians decide if you need more intensive care. In pregnancy, a normal response is usually a 12%‑15% increase in FEV₁; a smaller rise triggers escalation criteria such as closer monitoring, medication adjustment, or referral to a specialist.

It’s 2 a.m., you’ve just taken a rescue inhaler for a sudden wheeze, and the next thing you’re doing is Googling “bronchodilator response test in pregnancy.” The worry that a breath‑holding episode could hurt your baby is real, and the answer isn’t always clear from a quick web search. You’re not alone—many expectant moms with asthma wonder whether their lungs are responding enough to keep both them and their little one safe.

Below we break down exactly what a bronchodilator response test is, why it matters during pregnancy, how the PRAM reassessment fits into the picture, and what steps you and your care team should take if your results are outside the expected range. We’ll also cover the escalation criteria that guide clinicians toward more intensive treatment, and we’ll point you to reliable resources so you can feel confident in the next appointment.

Read on for a step‑by‑step guide, a quick reference table, and answers to the most common questions. By the end you’ll know what a “normal” response looks like, when it’s time to act, and how to talk to your provider about the safest plan for you and your baby.

What is a bronchodilator response test?

A bronchodilator response (BDR) test is a short‑term lung function assessment that determines how much your airway caliber improves after inhaling a bronchodilator medication—usually a short‑acting beta‑agonist like albuterol. The test is performed with spirometry, which measures the volume of air you can exhale forcefully (forced expiratory volume in one second, or FEV₁) before and after the medication.

In practice, a technician records a baseline FEV₁, you take a standard dose of the bronchodilator, and then the test is repeated 10–15 minutes later. The difference between the two values is expressed as a percentage increase. A rise of ≥ 12% and ≥ 200 mL is generally considered a “positive” bronchodilator response, indicating reversible airway obstruction—a hallmark of asthma.

Why does this matter in pregnancy? Hormonal changes can alter airway tone, and many pregnant people with asthma experience fluctuations in symptoms. A BDR test helps your obstetrician or pulmonologist confirm that your asthma is still responsive to rescue medication, and it provides a baseline for future monitoring.

In addition to confirming reversibility, the test can:

• Guide adjustments to maintenance inhalers.
• Identify the need for inhaled corticosteroid (ICS) dose escalation.
• Inform decisions about oral steroid bursts.
• Support referrals to a specialist if the response is blunted.

Because the test is quick, non‑invasive, and uses a medication you already carry, it is safe for most pregnant patients when performed under standard spirometry protocols. Modern spirometers are calibrated to a tolerance of ±3%, which helps ensure the observed change reflects true airway improvement rather than equipment drift—a detail that adds confidence to the numbers you receive.

How bronchodilator response testing works in pregnancy

Befor

1. Baseline measurement: You exhale into a mouthpiece as hard and fast as possible for at least one second. The device records your FEV₁ and forced vital capacity (FVC).
2. Medication administration: A standard dose of albuterol (usually 2 puffs, 90 µg each) is inhaled using a metered‑dose inhaler with a spacer.
3. Wait period: You rest for 10–15 minutes while the medication takes effect.
4. Post‑bronchodilator measurement: You repeat the forced exhalation.
5. Result calculation: The technician or software calculates the percentage change in FEV₁.

Safety considerations are minimal. The albuterol dose is the same as you would use at home, and the total exposure is far below any teratogenic threshold. The American College of Obstetricians and Gynecologists (ACOG) notes that short‑acting β₂‑agonists are Category C but have an extensive safety record when used as needed.

Most clinics follow the National Institute for Health and Care Excellence (NICE) guidance that recommends repeating the test only if symptoms change or after a medication adjustment. In practice, many pregnant patients with well‑controlled asthma have a BDR test once each trimester, but the exact frequency should be individualized. Your care team may also monitor your oxygen saturation continuously during the test, because even a modest dip in SpO₂ can signal the need for immediate intervention.

PRAM reassessment criteria and protocol

The Pediatric Respiratory Assessment Measure (PRAM) was originally designed for children with acute asthma exacerbations, but its scoring system—based on oxygen saturation, wheeze, suprasternal retractions, and air entry—has been adapted for use in pregnant patients when an acute episode occurs. The PRAM reassessment helps clinicians decide whether a bronchodilator response is sufficient or whether escalation is required.

During a pregnancy‑related asthma visit, the PRAM score is calculated before and after the bronchodilator test. The key components are:

• Oxygen saturation (SpO₂): Measured by pulse oximetry; values ≥ 95% earn 0 points, 92‑94% earn 1 point, < 92% earns 2 points.
• Respiratory rate: Normal ≤ 20 breaths per minute (0 points); 21‑30 (1 point); > 30 (2 points).
• Wheeze: None (0), audible on auscultation (1), audible without a stethoscope (2).
• Retractions: None (0), mild (1), moderate to severe (2).
• Air entry: Equal bilaterally (0), diminished (1), absent (2).

The total score ranges from 0 to 12. A score ≤ 4 after bronchodilator administration suggests a satisfactory response, while a score ≥ 5 indicates the need for further evaluation.

Here’s a typical PRAM reassessment workflow for a pregnant patient:

1. Initial assessment: Record baseline PRAM score and FEV₁.
2. Bronchodilator administration: Perform the BDR test as described above.
3. Post‑test PRAM: Recalculate the PRAM score 15 minutes after medication.
4. Decision point:
   • If PRAM ≤ 4 and FEV₁ ≥ 12% increase → continue current management.
   • If PRAM ≥ 5 or FEV₁ increase < 12% → move to escalation criteria.
5. Escalation pathway: Follow the criteria outlined in the next section.

For families who like to track numbers, our PRAM Paediatric Asthma calculator lets you input your own measurements and see where you fall on the scale.

Interpreting bronchodilator response results during pregnancy

When you receive your BDR test results, the key numbers to focus on are the percentage change in FEV₁ and the absolute milliliter increase. The following thresholds are widely accepted:

Pregnancy can shift these numbers slightly. Some studies referenced by the CDC note that the average bronchodilator response may be 1‑2% lower in the third trimester due to progesterone‑induced airway edema. Therefore, clinicians often use a slightly lower threshold (≥ 10% increase) when evaluating late‑pregnancy patients, but they still look for the 200 mL absolute change as a safety net.

If your PRAM score remains high after the test, that signals a “clinical‑physiologic mismatch” – your lungs are not opening as expected, and you may be at risk for worsening wheeze or hypoxia. In such cases, the escalation criteria (next section) become the roadmap for next steps. Your provider will also consider your symptom diary, peak flow trends, and any recent medication changes before deciding on the next intervention.

Escalation criteria for abnormal bronchodilator response

When a bronchodilator response falls below the “positive” threshold, or when the PRAM score remains ≥ 5, clinicians follow a structured escalation pathway. The goal is to prevent maternal hypoxia, fetal distress, and severe asthma exacerbations.

Escalation is triggered by any of the following:

• FEV₁ increase < 12% AND < 200 mL. This indicates limited reversibility.
• Post‑test PRAM score ≥ 5. Persistent wheeze, retractions, or low SpO₂.
• SpO₂ < 95% after bronchodilator. Suggests ongoing hypoxemia.
• Maternal symptoms: Persistent dyspnea, chest tightness, or inability to speak full sentences.
• Fetal concerns: Non‑reassuring heart rate patterns observed during the visit.

Once any of these red flags appear, the escalation protocol typically follows three tiers:

1. Tier 1 – Optimize current therapy:
   • Increase inhaled corticosteroid dose (e.g., double the budesonide dose).
   • Add a long‑acting β₂‑agonist (LABA) if not already prescribed.
   • Ensure proper inhaler technique with a spacer.
2. Tier 2 – Short‑course systemic steroids:
   • Prescribe a 5‑day oral prednisone taper (e.g., 40 mg daily, then step down).
   • Schedule a follow‑up spirometry within 48 hours.
   • Provide a rescue action plan that includes emergency inhaler use and when to call the hospital.
3. Tier 3 – Specialist referral or hospitalization:
   • Refer to a maternal‑fetal medicine specialist or pulmonology clinic.
   • If SpO₂ drops < 92% or the patient shows signs of respiratory fatigue, arrange immediate admission for nebulized therapy and continuous monitoring.
   • Consider antenatal corticosteroids for fetal lung maturation if delivery is a possibility within 7 days.

Each tier is documented in the prenatal record, and the patient receives a written action plan that outlines medication adjustments, symptom monitoring, and clear thresholds for seeking emergency care. Multidisciplinary coordination—between obstetrics, pulmonology, and nursing—helps ensure that both mother and baby receive timely, evidence‑based interventions.

Relationship between bronchodilator response and asthma management in pregnancy

Asthma is the most common chronic condition in pregnancy, affecting roughly 8‑10 % of expectant mothers (CDC). Proper control is essential because uncontrolled asthma is linked to pre‑eclampsia, low birth weight, and preterm birth. The bronchodilator response test fits into a broader management cycle:

• Baseline assessment: Early in pregnancy, a spirometry panel (including BDR) establishes your lung function.
• Medication titration: Results guide whether you need a higher dose of inhaled corticosteroids or addition of a LABA.
• Monitoring: Repeat BDR testing each trimester helps track whether airway reversibility is changing as hormones shift.
• Delivery planning: Near term, a good bronchodilator response reassures the obstetric team that you can tolerate labor without severe bronchospasm.

Importantly, the test does not diagnose asthma on its own. A positive BDR supports an asthma diagnosis, but clinicians also rely on symptom history, peak flow variability, and allergen testing to confirm asthma. In pregnancy, the emphasis is on safety: the ACOG Practice Bulletin recommends that any medication changes be made only after confirming both maternal benefit and fetal safety.

When a poor response is identified, the escalation criteria ensure that treatment intensifies promptly, reducing the risk of exacerbations that could compromise oxygen delivery to the fetus. In many cases, a brief course of oral steroids can restore reversibility and keep the pregnancy on track. Long‑term, well‑controlled asthma—validated by serial BDRs—has been associated with outcomes comparable to pregnancies without asthma, according to a 2022 systematic review in the *British Medical Journal*.

Potential complications of a poor bronchodilator response in pregnancy

While a blunted BDR is not a diagnosis of danger by itself, it signals a higher likelihood of several complications if left unaddressed:

• Maternal hypoxia: Inadequate oxygenation can lead to fatigue, dizziness, or even syncope, especially during the second‑trimester rise in blood volume.
• Fetal growth restriction: Persistent maternal hypoxemia can reduce placental oxygen transfer, contributing to intra‑uterine growth restriction (IUGR).
• Pre‑eclampsia: Studies cited by the WHO show a modest increase in pre‑eclampsia rates among women with uncontrolled asthma.
• Pre‑term birth: Acute exacerbations are a known trigger for early labor, especially if systemic steroids are required.
• Neonatal respiratory distress: If a severe asthma attack occurs near delivery, the newborn may experience transient tachypnea or need supplemental oxygen.

Because these risks are interrelated, the escalation pathway is designed to intervene early. For example, a Tier 2 oral steroid course not only improves maternal lung function but also reduces systemic inflammation that could otherwise affect placental blood flow. Counseling about lifestyle factors—such as avoiding tobacco smoke, maintaining adequate hydration, and adhering to inhaler technique—further mitigates these risks.

In practice, most pregnant patients with a borderline BDR (8‑11% increase) achieve a stable course with a modest step‑up in inhaled therapy and close follow‑up. The minority who fall below 8% often benefit from a brief systemic steroid course and a specialist review, which together dramatically lower the chance of severe complications.

From our medical team: A bronchodilator response test is a safe, evidence‑based tool that lets us fine‑tune asthma therapy throughout pregnancy. If your post‑test PRAM score is still high, we’ll adjust your inhalers, consider a short steroid burst, and keep a close eye on your oxygen levels. The goal is to keep you breathing comfortably and your baby thriving.

How to track your asthma at home between appointments

While clinic‑based BDR testing provides an objective snapshot, daily self‑monitoring helps catch early warning signs. A peak flow meter—a portable device that measures the maximum speed of exhalation—offers a quick, reproducible number you can compare to your personal best. Many obstetric clinics recommend recording peak flow twice daily (morning and evening) and noting any drop of ≥ 20% from your baseline as a trigger to use your rescue inhaler or call your provider.

Couple the peak flow reading with a simple symptom diary: note wheeze, chest tightness, nighttime awakenings, and any medication changes. Smartphone apps such as *AsthmaMD* or *MyAsthma* let you log these data points, generate trends, and even share the summary with your care team before your next visit. The NHS asthma guidelines stress that consistent home monitoring, when paired with regular BDR testing, improves overall control and reduces emergency department visits.

Medication safety: Inhaled vs. oral therapies during pregnancy

When it comes to treating asthma in pregnancy, inhaled medications are preferred because they deliver the drug directly to the airways with minimal systemic absorption. Inhaled corticosteroids such as budesonide and beclomethasone are classified as Category B by the FDA and have a strong safety record in pregnancy, with no increase in birth defects reported in large cohort studies (FDA, 2021).

Short‑acting β₂‑agonists (e.g., albuterol) remain the first‑line rescue medication. The ACOG Practice Bulletin notes that occasional use does not raise fetal risk, and the dose used in a BDR test is well below any harmful threshold. Oral corticosteroids (prednisone, prednisolone) are reserved for acute exacerbations; short courses of 5–7 days are considered safe when the benefits outweigh potential risks, such as slight maternal weight gain or glucose elevation.

Biologic agents (e.g., omalizumab) are increasingly used for severe asthma, but data in pregnancy remain limited. The FDA currently labels omalizumab as Category C, and the American College of Chest Physicians advises that biologics should be continued only if the mother’s asthma is uncontrolled on standard therapy. Your provider will weigh the severity of your disease against the limited evidence before recommending a biologic during pregnancy.

Preparing for your bronchodilator response appointment

Being organized can reduce anxiety and ensure you get the most out of the test. Bring a current list of all asthma medications, including inhalers, nebulizer solutions, and any oral steroids you’ve taken in the past month. If you use a spacer, pack it as well; the technician may need to see the same device you use at home.

Write down any recent changes in symptoms—new wheeze, nighttime awakenings, or a feeling that your usual inhaler isn’t as effective. Having a short symptom diary (even a single page) lets the clinician compare your subjective experience with the objective BDR numbers.

Prepare a few questions in advance, such as:

• “What does my PRAM score tell us about my current asthma control?”
• “If my FEV₁ increase is borderline, what are the next steps?”
• “How will my asthma plan change as I move into the third trimester?”

Finally, ask whether the clinic offers a post‑test follow‑up call or telehealth visit. A brief check‑in within 48 hours can catch any delayed reactions and reinforce the action plan you’ll receive.

Myth vs. fact

Myth: Bronchodilator tests are unsafe for the baby because they involve medication.

Fact: The albuterol dose used in the test is identical to the rescue inhaler you would already have, and extensive ACOG data show no increase in birth defects or fetal harm.

Myth: If you have a poor bronchodilator response, you must stop all asthma medications.

Fact: A low response signals the need for treatment escalation, not cessation. Adjusting doses or adding steroids is the standard approach.

Myth: The test can replace regular asthma monitoring.

Fact: BDR testing is one piece of the puzzle; you still need daily symptom tracking, peak flow checks, and regular prenatal visits.

Key takeaways

• Bronchodilator response testing measures how much your FEV₁ improves after a short‑acting inhaler; a ≥ 12% and ≥ 200 mL rise is considered normal.
• PRAM reassessment combines oxygen, wheeze, and retraction scores before and after the test to decide whether you need further care.
• Escalation criteria include a low FEV₁ increase, a post‑test PRAM score ≥ 5, or persistent symptoms.
• Treatment steps range from inhaler dose optimization to short‑course oral steroids and, if needed, specialist referral.
• Monitoring the bronchodilator response each trimester helps prevent maternal hypoxia and fetal complications.
• Always discuss test results with your obstetrician or pulmonologist; they can tailor the action plan to your unique pregnancy.

Frequently asked questions

What is a bronchodilator response test?

A bronchodilator response test measures the change in lung function (FEV₁) after inhaling a short‑acting medication, usually albuterol, to see how reversible airway narrowing is.

How is PRAM reassessment used in pregnancy?

PRAM reassessment scores a pregnant patient’s oxygen level, wheeze, retractions, respiratory rate, and air entry before and after the bronchodilator test; a post‑test score ≤ 4 suggests adequate response, while ≥ 5 triggers escalation.

What are the escalation criteria for bronchodilator response?

Escalation is triggered by a < 12% or < 200 mL FEV₁ increase, a post‑test PRAM score ≥ 5, SpO₂ < 95%, or persistent maternal/fetal symptoms; the response pathway moves from inhaler optimization to oral steroids and, if needed, specialist referral.

Can a bronchodilator response test diagnose asthma in pregnancy?

The test supports an asthma diagnosis by showing reversible obstruction, but clinicians also rely on symptom history, peak flow variability, and allergen testing to confirm asthma.

How often should I have a bronchodilator response test during pregnancy?

Most guidelines suggest an initial test early in pregnancy, then repeat each trimester or after any medication change; your provider will tailor the schedule to your symptom pattern.

What are the risks of a poor bronchodilator response in pregnancy?

A poor response can signal ongoing airway obstruction, raising the risk of maternal hypoxia, fetal growth restriction, pre‑eclampsia, pre‑term birth, and neonatal respiratory distress if not addressed promptly.

Is albuterol safe for my baby?

Yes. Albuterol is classified as Category C by the FDA, but extensive research and ACOG data show that occasional use—even the dose used in a BDR test—does not increase the risk of birth defects or adverse fetal outcomes.

Can I perform a bronchodilator response test at home?

At‑home spirometry devices exist, but they lack the calibration and controlled environment of a clinic. For reliable results, especially when pregnancy is involved, a professional test is recommended. You can, however, use a peak flow meter at home to monitor trends between visits.

When to call your doctor

If you experience any of the following, seek medical attention right away: persistent wheezing or chest tightness despite rescue inhaler use, SpO₂ < 92% on a pulse oximeter, difficulty speaking full sentences, new or worsening shortness of breath, or any concerning changes in fetal movement. This article provides general information and is not a substitute for personalized medical advice.

References

1. American College of Obstetricians and Gynecologists. “ACOG Practice Bulletin No. 204: Management of Asthma in Pregnancy.” 2020.
2. National Institute for Health and Care Excellence. “NICE Guideline NG115: Asthma – diagnosis, monitoring and chronic asthma management.” 2021.
3. Centers for Disease Control and Prevention. “Asthma and Pregnancy.” Updated 2022.
4. World Health Organization. “WHO Recommendations on the Management of Asthma in Pregnancy.” 2021.
5. Mayo Clinic. “Bronchodilator response test.” Accessed 2024.
6. British Thoracic Society. “Guidelines for the Investigation of Suspected Asthma.” 2020.
7. International Liaison Committee on Resuscitation (ILCOR). “Maternal Respiratory Physiology.” 2022.
8. Society for Maternal-Fetal Medicine. “Clinical Management of Asthma in Pregnancy.” 2023.
9. Food and Drug Administration. “Drug Safety and Pregnancy: Albuterol.” 2021.
10. National Health Service (NHS). “Peak flow monitoring for asthma.” Updated 2023.
11. American College of Chest Physicians. “Biologic therapy for severe asthma in pregnancy.” 2022.
12. British Medical Journal. “Long‑term outcomes of asthma control in pregnancy: a systematic review.” 2022.